The mortality of critically ill patients is persistently high and requires targeted therapy of pathophysiological disorders. One approach to optimize therapy is the use of the cytokine adsorber Cytosorb®, which has a CE certification for the indications hyperinflammation, rhabdomyolysis and liver failure and is therefore frequently used in patients with sepsis, polytrauma and acute liver failure. Although few clinical data describe the efficiency mostly retrospectively, there are no data on real-time elimination performance and saturation kinetics during the course of treatment. These questions should be answered by the present study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
57
Start of Cytosorb therapy is at the discretion of the attending physician
LMU munich
Munich, Bavaria, Germany
Change (percentage) in different cytokines (measured as a cytokine panel) measured pre- and post-CytoSorb® (extracorporeal) in intensive care patients with hyperinflammation
Measurement of a cytokine panel (20 different cytokines in one panel) before and after the filter at different times.
Time frame: 12 hours
Change (percentage) in myoglobin measured pre- and post-CytoSorb® (extracorporeal) in intensive care patients with rhabdomyolysis
Measurement of myoglobin before and after the filter at different times.
Time frame: 12 hours
Change (percentage) in bile acids (measured as a panel) measured pre- and post-CytoSorb® (extracorporeal) in intensive care patients with acute liver failure
Measurement of bile acids before and after the filter at different times.
Time frame: 12 hours
Change (percentage) in norepinephrine demand before and after the use of CytoSorb®
Time frame: 2 years
Change ( percentage ) of liver toxic substances (e.g. bile acids) in patients´ blood due to the use of CytoSorb®
Time frame: 2 years
Change ( percentage ) of myoglobin in patients´ blood due to the use of CytoSorb®
Time frame: 2 years
Difference (percentage) between predicted mortality and real mortality of patients treated with CytoSorb®
Mortality can be predicted by intensive care scores. We will investigate the difference between actual and predicted mortality.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.